Skip to main content

JAK/TYK2

Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW
Dr. John Cush @RheumNow( View Tweet )

EULAR 2024 Rheumatology Roundup (6.21.2024)

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt
Dr. John Cush @RheumNow( View Tweet )
Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo
Dr. John Cush @RheumNow( View Tweet )
Impact of regulatory warning on JAK inhibitors JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death. https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg
Dr. John Cush @RheumNow( View Tweet )
RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
Dr. John Cush @RheumNow( View Tweet )

EULAR 2024 – Day 4 Report

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article

Achieving drug-free remission in axSpA

EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients. In axSpA patients with less than 1 year of disease symptoms, male sex, abstinence from smoking and lower BASDAI score at baseline were associated with higher

Read Article

Choices in GCA

There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Read Article
Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org

Janet Pope @Janetbirdope( View Tweet )

#EULARBEST RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i IL17i JAKi @eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo

Janet Pope @Janetbirdope( View Tweet )

EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Peter Nash @drpnash( View Tweet )

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Peter Nash @drpnash( View Tweet )

lets put this bed now @RheumNow #EULAR https://t.co/r0SVoOk47O
Peter Nash @drpnash( View Tweet )
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024

Peter Nash @drpnash( View Tweet )

#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
LBA0001 UPA in GCA- Phase 2 RCT 15mg UPA with 26w steroid taper showed ⬆️ efficacy ⬇️ steroid use vs placebo with 52w steroid taper Potential new target on the horizon for #GCA?? @RheumNow #EULAR2024

Mrinalini Dey @DrMiniDey( View Tweet )

POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i @SteZhao @RheumNow #EULAR2024

Mrinalini Dey @DrMiniDey( View Tweet )

1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd
Peter Nash @drpnash( View Tweet )
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria: OP0195 LBA0005 POS0803 OP0138 https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Dr. John Cush @RheumNow( View Tweet )
Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases @ARD_BMJ( View Tweet )
EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024

Peter Nash @drpnash( View Tweet )

Impact of regulatory warning on JAK inhibitors

The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using

Read Article
#wasup in #GCA? #upadacitinib +RCT in #temporal #arteritis LBA0001 Residual #inflammation in 1/3 of pts at 6 mo #Rx w #TCZ on repeat TA Bx OP0621 #PMR cases #Leflunomide beats #MTX for #pred sparing ⬇️relapses But MTX dose was low POS0280 #EULAR2024 @RheumNow @eular_org

Janet Pope @Janetbirdope( View Tweet )

New #JAKi #disease #results #Baricitinib in #alopecia #areata esp 4mg/d #Upadacitinib in Crohn’s #Upa in #polyarticular #JIA & kid #PsA +RCT of UPA in #GCA Awaiting results of #SLE With #deucravicitinib & UPA #RCTs #EULAR2024 @eular_org @RheumNow

Janet Pope @Janetbirdope( View Tweet )